Voluntary nationwide recall: Sulfamethoxazole/Trimethoprim (Amneal – June)

Jun. 2025Pharmacy Updates

Amneal Pharmaceutical LLC is recalling certain lots of Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80 mg. Sulfamethoxazole/Trimethoprim is used for the treatment of certain bacterial infections.

This drug is being recalled because tablets may have black spots due to microbial contamination. These black spots were reported during a product quality complaint. Using a drug that has microbial contamination may cause life-threatening illness. The use of the defective product in patients with underlying immunosuppressive conditions increases the concern for serious infections.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Sulfamethoxazole/Trimethoprim, you should stop using the product and return it to Amneal.

As of June 2, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Amneal Pharmaceutical LLC at 833-582-0812. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

Important announcement – Telehealth submissions

As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.
Sep. 2025Important Notices

October 2025 UPMC for You and UPMC Community HealthChoices Formulary Update

Effective October 1st, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to non-participation in the Medicaid Drug Rebate Program.
Sep. 2025Pharmacy Updates

Biosimilar Medication Formulary Updates

Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products
Sep. 2025Pharmacy Updates